Dabigatran 150 mg reduced stroke and systemic embolism rates compared to warfarin, while major hemorrhage rates remained similar.
Does dabigatran reduce stroke and systemic embolism in patients with atrial fibrillation compared to warfarin?
Dabigatran offers a dose-dependent alternative to warfarin in atrial fibrillation, with the 150 mg dose improving efficacy without increasing major bleeding, and the 110 mg dose reducing bleeding with similar efficacy.
Tasa de eventos absoluta: 0% vs 0%
In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage. Dabigatran administered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage. (ClinicalTrials.gov number, NCT00262600.)
Connolly et al. (Sun,) reported a other. Dabigatran 150 mg reduced stroke and systemic embolism rates compared to warfarin, while major hemorrhage rates remained similar.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: